Clinical Trial Update: Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial [Phase 1]

View source ↗

Summary

Phase I open-label, dose-escalation trial of a CRISPR/Cas13-RNA targeting therapy for neovascular age-related macular degeneration; the study is not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• CRISPR/Cas13-RNA targeting therapy

Snippet

Sponsor: HuidaGene Therapeutics Co., Ltd. | Conditions: Neovascular Age-Related Macular Degeneration (nAMD) | Phase 1 | Status: NOT_YET_RECRUITING